3 Forbes Road
United States - Map
Agenus Inc., a biopharmaceutical company, develops novel immunotherapeutics with a portfolio of checkpoint modulators and anti-cancer vaccines. Its three platforms include checkpoint modulators, heat shock protein based vaccines, and adjuvants. The companys proprietary discovery engine Retrocyte Display generates therapeutic antibody drug candidates using an approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. Its portfolio of checkpoint modulator programs is advancing in preclinical development; and various heat shock protein vaccines are in Phase 2 studies to treat glioblastoma multiforme and metastatic melanoma, as well as the adjuvant platform is partnered with GlaxoSmithKline and Janssen and includes various candidates in late-stage trials. The company also has 23 programs in clinical development. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
|Agenus Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 7. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 7; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Garo H. Armen Ph.D.,
Founder, Exec. Chairman, Chief Exec. Officer and Pres
|Ms. Christine M. Klaskin ,
Principal Financial Officer, Principal Accounting Officer and VP of Fin.
|Ms. Karen Higgins Valentine ,
VP, Gen. Counsel and Sec.
|Ms. Kerry A. Wentworth ,
VP of Clinical Regulatory & Quality
|Dr. Pramod K. Srivastava Ph.D.,
Co Founder, Chairman of the Scientific & Medical Advisory Board and Consultant
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|